JOHN VIERLING to Cost-Benefit Analysis
This is a "connection" page, showing publications JOHN VIERLING has written about Cost-Benefit Analysis.
Connection Strength
0.038
-
Cost-Effectiveness Analysis of Hepatitis B Virus Screening and Management in Patients With Hematologic or Solid Malignancies Anticipating Immunosuppressive Cancer Therapy. JCO Clin Cancer Inform. 2019 03; 3:1-12.
Score: 0.030
-
Posttransplantation: future therapies. Semin Liver Dis. 2000; 20 Suppl 1:19-24.
Score: 0.008